Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Biological Product
73%
Psoriasis
60%
Patient Characteristics
50%
Hazard Ratio
44%
Psoriatic Arthritis
43%
Ustekinumab
42%
Survival Rate
38%
Diseases
35%
Actinic Keratosis
33%
Prevalence
33%
Dermatology
33%
Outpatient
33%
Real-World Evidence
33%
Pustulosis Palmaris Et Plantaris
33%
Predictive Factor
33%
Kidney Transplantation
33%
Mycosis fungoides
33%
Ixekizumab
33%
Secukinumab
33%
Treatment Option
33%
Registry Analysis
33%
Interleukin 17 Antibody
33%
Etanercept
22%
Adalimumab
22%
Solid Organ Transplantation
16%
Patient Care
16%
Treatment Response
16%
Effective Treatment
16%
Systemic Therapy
14%
Diagnostic Delay
14%
Phototherapy
14%
Psoriasis Area and Severity Index
11%
Cohort Analysis
11%
Interleukin 23p19
9%
Psoriasis Vulgaris
9%
Median Survival Time
9%
Disease Duration
9%
Squamous Cell Carcinoma
7%
Tumor
5%
Chemotherapy
5%
T Cell
5%
Lymph Duct
5%
Bone Marrow Biopsy
5%
Electron Therapy
5%
Contraindication
5%
Immunosuppressive Treatment
5%
Gamma Delta T-Cell
5%
Immunosuppressant
5%
Biopsy Technique
5%
Pharmacology, Toxicology and Pharmaceutical Science
Psoriasis
100%
Biological Product
53%
Survival Rate
38%
Ustekinumab
33%
Interleukin 23p19
33%
Secukinumab
33%
Interleukin 17 Antibody
33%
Interleukin 23 Antibody
33%
Apremilast
33%
Ixekizumab
33%
Psoriatic Arthritis
22%
Etanercept
22%
Adalimumab
22%
Interleukin 23
20%
Cohort Study
17%
Adverse Event
13%
Diseases
9%
Psoriasis Vulgaris
6%
Tildrakizumab
6%
Risankizumab
6%
Guselkumab
6%
Clinical Trial
6%
Infection
6%
Drug Delivery System
6%
Interleukin 17
6%
Immunology and Microbiology
Biological Product
53%
Pustulosis
33%
Transcriptomics
33%
Interleukin 17 Antibody
33%
Secukinumab
33%
Ixekizumab
33%
Interleukin 23 Antibody
33%
Survival Rate
33%
Interleukin 23 Subunit Alpha
33%
Ustekinumab
33%
Etanercept
22%
Adalimumab
22%
Psoriatic Arthritis
22%
Interleukin 23
20%
Tildrakizumab
6%
Guselkumab
6%
Risankizumab
6%
Interleukin 17
6%
Infection
6%
Infectious Disease
6%
Drug Targeting
6%
Drug Hypersensitivity
5%